1. Início
  2. Publicações
  3. Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries

Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries

Data de publicação:

Autores da FMUP

  • Nuno Miguel De Sousa Lunet

    Autor

Participantes de fora da FMUP

  • Yoo, SGK
  • Chung, GS
  • Bahendeka, SK
  • Sibai, AM
  • Damasceno, A
  • Farzadfar, F
  • Rohloff, P
  • Houehanou, C
  • Norov, B
  • Karki, KB
  • Azangou-Khyavy, M
  • Marcus, ME
  • Aryal, KK
  • Brant, LCC
  • Theilmann, M
  • Cífková, R
  • Gurung, MS
  • Mwangi, JK
  • Martins, J
  • Haghshenas, R
  • Sturua, L
  • Vollmer, S
  • Bärnighausen, T
  • Atun, R
  • Sussman, JB
  • Singh, K
  • Saeedi Moghaddam, S
  • Guwatudde, D
  • Geldsetzer, P
  • Manne-Goehler, J
  • Huffman, MD
  • Davies, JI
  • Flood, D

Unidades de investigação

Abstract

IMPORTANCE Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD. OBJECTIVE To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years. EXPOSURES Countries' per capita income levels and world region; individuals' socioeconomic demographics. MAIN OUTCOMES AND MEASURES Self-reported use of aspirin for secondary prevention of CVD. RESULTS The overall pooled sample included 124505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10589 individuals had a self-reported history of CVD (8.1% [95% CI, 7.6%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. CONCLUSION AND RELEVANCE Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy.

Dados da publicação

ISSN/ISSNe:
1538-3598, 0098-7484

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  American Medical Association

Tipo:
Article
Páginas:
715-724
PubMed:
37606674
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 1

Citações Recebidas na Scopus: 10

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • MEDICATION USE; COLLABORATIVE METAANALYSIS; THERAPY

Campos de Estudo

Financiamento

Michigan Center for Diabetes Translational Research (P30DK092926)
University of Michigan Caswell Diabetes Institute Clinical Translational Research Scholars Program
University of Michigan Claude D. Pepper Older Americans Independence Center (5P30AG024824)
US National Heart, Lung, and Blood Institute (K23HL161271)

Projetos associados

Breast cancer heterogeneity - etiology, clinical management, use of health resources and survival

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2022

Longitudinal Assessment of Cognitive Decline in Breast and Prostate Cancer Survivors

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico (Cognitive Decline) . 2022

Healthcare use among cancer patients and their partners in different phases of the cancer pathway

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2021

Reshaping organized cervical cancer screening: strategies to increase the adherence and reduce invitation costs

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

Using pooled analyses based on individual participant data for a finer assessment of gastric cancer etiology

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2019

Partilhar a publicação